Surgery and target agents for renal cell carcinoma treatment: the path between proper interaction.

Carlo Ganini, Bruno Rovereto, Camillo Porta

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Renal cell carcinoma accounts for 3% of all solid tumors and currently causes about 3,500 deaths/year in the UK. Once an orphan disease, it has undergone an impressive change in its natural history with an improvement in overall survival, thanks to the development of new target agents. In its management, renal cell carcinoma has been treated with both surgical and medical approaches. Nowadays, many more drugs are available, especially in the metastatic setting, so that we should reconsider the peculiar role of surgery and its interaction with target agents. Cytoreductive nephrectomy still plays a major role in the management of the disease, though no really solid data have been still obtained. Adjuvant and neoadjuvant settings, instead, are still under evaluation, especially new adjuvant therapies involving the numerous target agents we have. Finally, metastasectomy has a controversial role, with some evidence of more efficacy than the medical treatment, though it shows too many biases to be considered certain. The picture that comes out suggests a complex frame, in which we have great power to act, but in which we need to better comprehend the interactions that could be created between surgery and medical therapies, to achieve an optimal multimodal treatment for renal cell carcinoma.

Original languageEnglish
Pages (from-to)9-15
Number of pages7
JournalUrologia
Volume78 Suppl 18
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Renal Cell Carcinoma
Metastasectomy
Combined Modality Therapy
Disease Management
Rare Diseases
Natural History
Nephrectomy
Therapeutics
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Surgery and target agents for renal cell carcinoma treatment : the path between proper interaction. / Ganini, Carlo; Rovereto, Bruno; Porta, Camillo.

In: Urologia, Vol. 78 Suppl 18, 10.2011, p. 9-15.

Research output: Contribution to journalArticle

@article{a196fbcc317943678ca6fbf3b8c0ffda,
title = "Surgery and target agents for renal cell carcinoma treatment: the path between proper interaction.",
abstract = "Renal cell carcinoma accounts for 3{\%} of all solid tumors and currently causes about 3,500 deaths/year in the UK. Once an orphan disease, it has undergone an impressive change in its natural history with an improvement in overall survival, thanks to the development of new target agents. In its management, renal cell carcinoma has been treated with both surgical and medical approaches. Nowadays, many more drugs are available, especially in the metastatic setting, so that we should reconsider the peculiar role of surgery and its interaction with target agents. Cytoreductive nephrectomy still plays a major role in the management of the disease, though no really solid data have been still obtained. Adjuvant and neoadjuvant settings, instead, are still under evaluation, especially new adjuvant therapies involving the numerous target agents we have. Finally, metastasectomy has a controversial role, with some evidence of more efficacy than the medical treatment, though it shows too many biases to be considered certain. The picture that comes out suggests a complex frame, in which we have great power to act, but in which we need to better comprehend the interactions that could be created between surgery and medical therapies, to achieve an optimal multimodal treatment for renal cell carcinoma.",
author = "Carlo Ganini and Bruno Rovereto and Camillo Porta",
year = "2011",
month = "10",
doi = "10.5301/RU.2011.8769",
language = "English",
volume = "78 Suppl 18",
pages = "9--15",
journal = "Urologia",
issn = "0391-5603",
publisher = "Wichtig Publishing",

}

TY - JOUR

T1 - Surgery and target agents for renal cell carcinoma treatment

T2 - the path between proper interaction.

AU - Ganini, Carlo

AU - Rovereto, Bruno

AU - Porta, Camillo

PY - 2011/10

Y1 - 2011/10

N2 - Renal cell carcinoma accounts for 3% of all solid tumors and currently causes about 3,500 deaths/year in the UK. Once an orphan disease, it has undergone an impressive change in its natural history with an improvement in overall survival, thanks to the development of new target agents. In its management, renal cell carcinoma has been treated with both surgical and medical approaches. Nowadays, many more drugs are available, especially in the metastatic setting, so that we should reconsider the peculiar role of surgery and its interaction with target agents. Cytoreductive nephrectomy still plays a major role in the management of the disease, though no really solid data have been still obtained. Adjuvant and neoadjuvant settings, instead, are still under evaluation, especially new adjuvant therapies involving the numerous target agents we have. Finally, metastasectomy has a controversial role, with some evidence of more efficacy than the medical treatment, though it shows too many biases to be considered certain. The picture that comes out suggests a complex frame, in which we have great power to act, but in which we need to better comprehend the interactions that could be created between surgery and medical therapies, to achieve an optimal multimodal treatment for renal cell carcinoma.

AB - Renal cell carcinoma accounts for 3% of all solid tumors and currently causes about 3,500 deaths/year in the UK. Once an orphan disease, it has undergone an impressive change in its natural history with an improvement in overall survival, thanks to the development of new target agents. In its management, renal cell carcinoma has been treated with both surgical and medical approaches. Nowadays, many more drugs are available, especially in the metastatic setting, so that we should reconsider the peculiar role of surgery and its interaction with target agents. Cytoreductive nephrectomy still plays a major role in the management of the disease, though no really solid data have been still obtained. Adjuvant and neoadjuvant settings, instead, are still under evaluation, especially new adjuvant therapies involving the numerous target agents we have. Finally, metastasectomy has a controversial role, with some evidence of more efficacy than the medical treatment, though it shows too many biases to be considered certain. The picture that comes out suggests a complex frame, in which we have great power to act, but in which we need to better comprehend the interactions that could be created between surgery and medical therapies, to achieve an optimal multimodal treatment for renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84856267163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856267163&partnerID=8YFLogxK

U2 - 10.5301/RU.2011.8769

DO - 10.5301/RU.2011.8769

M3 - Article

C2 - 22081423

AN - SCOPUS:84856267163

VL - 78 Suppl 18

SP - 9

EP - 15

JO - Urologia

JF - Urologia

SN - 0391-5603

ER -